IDiyas

For the Inventor, By the Inventor

Virum, Denmark

Thomas Boerglum Kjeldsen

USPTO Granted Patents = 20 

Average Co-Inventor Count = 4.7

ph-index = 5

Forward Citations = 54(Granted Patents)


Company Filing History:

goldMedal20 out of 1,777 
 
Novo Nordisk A/s
 patents

Years Active: 2002-2024

Loading Chart...
20 patents (USPTO):Explore Patents
1. 12152063 - Insulin analogues and uses thereof (2024-11-26),
2. 12122818 - Insulin analogues and uses thereof (2024-10-22),
3. 11649269 - Bifunctional compounds comprising insulin peptides and EGF(A) peptides (2023-05-16),
4. 11498951 - Insulin analogues and uses thereof (2022-11-15),
5. 11471537 - Oligomer extended insulin-Fc conjugates (2022-10-18),
6. 11208452 - Insulins with polar recombinant extensions (2021-12-28),
7. 10259856 - Protease stabilized acylated insulin analogues (2019-04-16),
8. 10040839 - Insulin derivatives and the medical uses hereof (2018-08-07),
9. 9896496 - Derivative of an insulin analogue (2018-02-20),
10. 9688737 - Protease stabilized acylated insulin analogues (2017-06-27),
11. 9512195 - Insulin derivatives containing additional disulfide bonds (2016-12-06),
12. 9187547 - Human insulin analogues and derivatives comprising cysteine substitutions (2015-11-17),
13. 9045560 - Protease stabilized, acylated insulin analogues (2015-06-02),
14. 9035020 - Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids (2015-05-19),
15. 8962794 - Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids (2015-02-24),

Title: Innovations in Diabetes Treatment: The Contributions of Thomas Boerglum Kjeldsen

Introduction

Thomas Boerglum Kjeldsen, an esteemed inventor based in Virum, Denmark, has made significant strides in the field of diabetes treatment. With an impressive portfolio of 20 patents, he has dedicated his career to developing innovative solutions to improve the lives of those affected by diabetes.

Latest Patents

Among his most notable recent inventions are the "Insulin analogues and uses thereof." This groundbreaking invention focuses on therapeutic applications relating to diabetes. Specifically, it pertains to insulin analogues of human insulin. The invention encompasses pharmaceutical compositions that utilize these insulin analogues for the treatment or prevention of various medical conditions associated with diabetes.

Career Highlights

Kjeldsen has achieved remarkable success in his career at Novo Nordisk A/S, a leading global healthcare company that specializes in diabetes care. His work has not only advanced the understanding of insulin therapies but has also paved the way for more effective and patient-friendly treatment options.

Collaborations

Throughout his career, Thomas has collaborated with talented individuals in the field, including his coworkers Peter Madsen and Frantisek Hubalek. Their joint efforts have contributed to innovative advancements in diabetes treatment, showcasing the importance of teamwork in research and development.

Conclusion

In conclusion, Thomas Boerglum Kjeldsen has made invaluable contributions to diabetes treatment through his patented innovations. His work at Novo Nordisk A/S highlights the impact of dedicated inventors in the pharmaceutical industry, continuing to drive advancements that make a difference in patients' lives worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…